Last reviewed · How we verify
NCT04197492
Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
Phase 2 trial testing Hypofractionated Stereotactic Radiotherapy in Malignant Glioma in 22 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Huashan Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 16 December 2019 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Hypofractionated Stereotactic Radiotherapy
- Anlotinib — full drug profile →
Conditions studied
- Malignant Glioma — all drugs for Malignant Glioma →
Sponsor
Huashan Hospital
Who can join
Adults 18 to 70, any sex, with Malignant Glioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase II Study of Hypofractionated Stereotactic Radiotherapy (HSRT) With Anlotinib in Patients With Recurrent High-Grade Glioma. The primary endpoint is overall survival after radiotherapy. Secondary endpoints included progress-free survival, objective response rate, cognitive function, quality of life, toxicity.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Glioblastoma Treatment: State-of-the-Art and Future Perspectives.
Rodríguez-Camacho A, Flores-Vázquez JG, Moscardini-Martelli J, Torres-Ríos JA, et al · · 2022 · cited 91× · PMID 35806212 · DOI 10.3390/ijms23137207 -
Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
Guan Y, Xiong J, Pan M, Shi W, et al · · 2021 · cited 19× · PMID 33546642 · DOI 10.1186/s12885-021-07856-y -
Radiotherapy of High-Grade Gliomas: First Half of 2021 Update with Special Reference to Radiosensitization Studies.
Frosina G. · · 2021 · cited 14× · PMID 34445646 · DOI 10.3390/ijms22168942 -
Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report.
Guan Y, Li J, Gong X, Zhu H, et al · · 2022 · cited 9× · PMID 35448002 · DOI 10.3390/brainsci12040471 -
The clinical benefit of adding anlotinib to chemoradiothearpy in high-grade gliomas: a systematic review, meta-analysis, and specific analysis on glioblastoma.
Habibi MA, Hojjat SH, Hajikarimloo B, Dashti M, et al · · 2026 · PMID 41729324 · DOI 10.1007/s10238-025-02024-z -
Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at First Recurrence: A Preliminary Report
Guan Y, Li J, Gong X, Zhu H, et al · · 2021 · DOI 10.21203/rs.3.rs-181453/v1 -
Safety and Efficacy of Hypofractionated Stereotactic Radiosurgery for High-Grade Gliomas at First Recurrence: A Single-Center Experience
Guan Y, Xiong J, Pan M, Shi W, et al · · 2020 · DOI 10.21203/rs.3.rs-113747/v1 -
Safety and Efficacy of Hypofractionated Stereotactic Radiosurgery for High-Grade Gliomas at First Recurrence: A Single-Center Experience
Guan Y, Xiong J, Pan M, Shi W, et al · · 2020 · DOI 10.21203/rs.3.rs-62212/v1
Verify or expand the search:
- PubMed search for NCT04197492
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hypofractionated Stereotactic Radiotherapy
Trials testing the same drug.
- NCT04805255 — A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT · recruiting
Other recruiting trials for Malignant Glioma
Currently open trials in the same condition.
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07447531 — T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas · NA · recruiting
- NCT06470711 — Mapping of Electrical Properties in the Brain · recruiting
- NCT05717153 — Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma · EARLY_PHASE1 · recruiting
- NCT05030298 — Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial · Phase 1 · recruiting
Other Huashan Hospital trials
Trials by the same sponsor.
- NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
- NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
- NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
- NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
- NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04197492 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
- Last refreshed: 5 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04197492.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing